Zynerba Pharmaceuticals’ Cannabis-Based Epilepsy Gel Fails Study

Zynerba Pharmaceuticals' Cannabis-Based Epilepsy Gel Fails Study

Flickr / Thomas Hawk / (CC BY-NC 2.0)

Zynerba Pharmaceuticals Inc said on Monday its synthetic cannabis-based gel to treat epilepsy failed a mid-stage study, sending the U.S. drug developer’s shares plunging 50 percent.

In the study, two doses of Zynerba’s gel — also its lead experimental drug — were tested in adults suffering from epilepsy with partial seizures, those that occur when epileptic activity takes part in a localized part of the brain.

Neither dose induced a statistically significant improvement in seizure frequency, when compared to a placebo.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts